| Title |
Platinum-based chemotherapy in triple-negative advanced breast cancer
|
|---|---|
| Published in |
Breast Cancer Research and Treatment, July 2014
|
| DOI | 10.1007/s10549-014-3033-4 |
| Pubmed ID | |
| Authors |
Cynthia Villarreal-Garza, Daniel Khalaf, Nathaniel Bouganim, Mark Clemons, Omar Peña-Curiel, Berenice Baez-Revueltas, Alexander Kiss, Farah Kassam, Katherine Enright, Sunil Verma, Kathleen Pritchard, Jeff Myers, Rebecca Dent |
| Abstract |
The purpose of this study was to evaluate the efficacy of platinum-based chemotherapy (PBC) versus conventional non-PBC regimens in a metastatic triple-negative breast cancer (TNBC) setting. We reviewed the electronic patient records of patients with confirmed metastatic TNBC at four major cancer centres in Canada. All patients were allocated into two groups based on type of chemotherapy received (PBC vs. non-PBC) and line of treatment (first-, second-, or third-line). The primary objective of this study was to evaluate the efficacy of PBC in metastatic TNBC in terms of median duration of overall survival (OS) from diagnosis of distant metastatic disease and compare it with the efficacy of conventional non-platinum-based chemotherapy in metastatic TNBC after controlling for known prognostic factors. A total of 153 metastatic TNBC patients were identified, 58 treated with PBC and 95 with non-PBC. The median time in first-line PBC versus non-PBC was not different between the two groups (2 vs. 2 months, p = 0.9), the median time on treatment in second and third-line therapy was longer for the PBC group compared to the conventional treated group (4 vs. 1 months, p = 0.004; 4 vs. 0.5 months, p = 0.004, respectively). Patients who received PBC had a longer OS compared to those managed conventionally (14.5 vs. 10 months, p = 0.041). This study evaluates the survival outcomes in a homogenous group of TNBC metastatic patients treated with or without PBC. Our results confirmed our hypothesis of a better OS among PBC-treated TNBC patients compared to conventionally managed TNBC patients. Currently ongoing Phase III trials assessing the benefit of PBC versus other chemotherapeutic regimens in advanced TNBC will help define the role of these agents for the management of this breast cancer subtype. |
X Demographics
The data shown below were collected from the profile of 1 X user who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 1 | 100% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 1 | 100% |
Mendeley readers
The data shown below were compiled from readership statistics for 72 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Japan | 1 | 1% |
| Italy | 1 | 1% |
| Unknown | 70 | 97% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Master | 13 | 18% |
| Researcher | 11 | 15% |
| Other | 8 | 11% |
| Student > Bachelor | 5 | 7% |
| Student > Postgraduate | 5 | 7% |
| Other | 17 | 24% |
| Unknown | 13 | 18% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 21 | 29% |
| Agricultural and Biological Sciences | 11 | 15% |
| Biochemistry, Genetics and Molecular Biology | 9 | 13% |
| Chemistry | 4 | 6% |
| Nursing and Health Professions | 4 | 6% |
| Other | 9 | 13% |
| Unknown | 14 | 19% |
Attention Score in Context
This research output has an Altmetric Attention Score of 1. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 08 July 2014.
All research outputs
#18,374,472
of 22,758,248 outputs
Outputs from Breast Cancer Research and Treatment
#3,713
of 4,652 outputs
Outputs of similar age
#161,604
of 225,828 outputs
Outputs of similar age from Breast Cancer Research and Treatment
#34
of 49 outputs
Altmetric has tracked 22,758,248 research outputs across all sources so far. This one is in the 11th percentile – i.e., 11% of other outputs scored the same or lower than it.
So far Altmetric has tracked 4,652 research outputs from this source. They typically receive a little more attention than average, with a mean Attention Score of 7.2. This one is in the 11th percentile – i.e., 11% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 225,828 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 15th percentile – i.e., 15% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 49 others from the same source and published within six weeks on either side of this one. This one is in the 12th percentile – i.e., 12% of its contemporaries scored the same or lower than it.